Milsaperidone, a new chemical entity, is the major active metabolite of iloperidone (Fanapt) and had been demonstrated to be ...

Milsaperidone is an active metabolite of iloperidone ...

Baylor College of Medicine received nearly $10 million in funding from the NIH BRAIN Initiative to study effective treatments for the depressive phase of bipolar disorder. In the span of five years, ...

The company expects the Bysanti drug to be available in the market in the third quarter of 2026. ・The drug is being tested as ...

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

The biopharmaceutical company said Friday Bysanti tablets were approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as for the treatment of ...

Synthetic psilocybin with psychotherapy was effective and safe for patients with treatment-resistant bipolar depression, a small nonrandomized controlled trial suggested. Among 15 people with bipolar ...

Hayes et al 12 conducted one of the most recent large studies to compare lithium with newer second-generation antipsychotics as maintenance monotherapy for bipolar disorder. The authors concluded that ...

In 2016, Matt Baszucki was a freshman in college and taking engineering classes when he began experiencing manic symptoms. “It was like sleeping less and less, having grandiose thoughts, rapid speech, ...